Chemicon International Inc.

News & Analysis

chemicon international inc. - All News and Analysis

• Chemicon International and Australian Stem Cell Centre Announce Exclusive Agreement to Commercialize Stem Cell Products

  - 2006-04-21

  ATLANTA -- Serologicals Corporation (NASDAQ: SERO) and the Australian Stem Cell Centre ASCC announced today that they have signed an agreement whereby Chemicon International, Inc., Serologicals' wholly-owned subsidiary, has obtained exclusive rights to commercialize, market and distribute stem cell reagents developed at the ASCC to scientists all over the world....

  Tags: Chemicon International Inc., Serologicals Corp.

• Chemicon International and Stem Cell Sciences Announce Launch of ESGRO Complete™ Product Line

  - 2006-02-28

  ATLANTA -- New Grade of Serum and Feeder-Free Media for Mouse Embryonic Stem Cell Expansion Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Stem Cell Sciences plc (LSE:STEM, SCS) are launching the ESGRO CompleteTM product line for murine embryonic stem ES cell culture,...

  Tags: Serologicals Corp.

• Chemicon International and Cellumen Announce an R & D Agreement to Commercialize a Systems Cell Biology Approach to Cytotoxicity Profiling in Drug Discovery

  - 2006-02-07

  ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, has entered into a research and development agreement with Cellumen, Inc., to commercialize a cytotoxicity profiling panel and services designed with Chemicon and Upstate's market-leading cellular assay reagents and Cellumen's system cell biology approach. Chemicon...

  Tags: Serologicals Corp.

• Chemicon International and MorphoSys Enter into Worldwide Licensing Agreement for Research Antibodies

  - 2006-01-10

  ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) have signed a three-year agreement for the distribution of HuCALR-based recombinant research antibodies through Chemicon's worldwide sales network. MorphoSys's Antibodies by Design unit will...

  Tags: MorphoSys AG, Serologicals Corp.

• Chemicon International, Inc. Enters into License Agreement with RheoGene, Inc. to Commercialize Research Products Utilizing RheoSwitch® Inducible Gene Regulation Technology

  - 2005-11-28

  ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, and RheoGene, Inc. (Norristown, PA) have signed a semi-exclusive license to use RheoGene's RheoSwitchR System and related technologies within Chemicon's research product lines focused on specialty research markets, including Chemicon's growing...

  Tags: Chemicon International Inc., RheoGene Inc., Serologicals Corp.

• Stem Cell Experts Engage at 2nd Annual Christopher Reeve Hot Topics in Stem Cell Biology Satellite Symposium

  - 2005-11-08

  ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, is sponsoring the 2nd Annual Christopher Reeve Hot Topics in Stem Cell Biology Satellite Symposium, to be held during the 2005 Society for Neuroscience 35th Annual Meeting. The symposium is coordinated...

  Tags: Chemicon International Inc., Serologicals Corp.

• Chemicon International Announces Agreement with Axordia for Exclusive Co-Development of Human Embryonic Stem Cell Antibody Markers

  - 2005-09-30

  ATLANTA & SHEFFIELD, United Kingdom -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Axordia Ltd. have signed an exclusive agreement to co-develop new antibody markers from Axordia's proprietary human embryonic stem ES cell lines. Under the terms of this agreement, Axordia will contribute...

  Tags: Axordia Ltd., Chemicon International Inc., Serologicals Corp.

• Chemicon International, Inc. Releases Innovative Infectious Disease Detection Product

  - 2005-09-22

  ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, has launched a new proprietary AmplifluorR ID Pan-Enterovirus Detection Reagent. This product rapidly detects Pan-Enterovirus. This is the first of many infectious disease detection products to be offered utilizing Chemicon's patented...

  Tags: Atlanta, Computer Associates International Inc., INTERNET, PRODUCTIVITY, Serologicals Corp.

• Chemicon International, Inc. Enters into a License to Commercialize Research Products Utilizing Human Embryonic Stem Cell Technology from Wisconsin Alumni Research Foundation

  - 2005-07-25

  ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, and the Wisconsin Alumni Research Foundation WARF have signed a license to commercialize research products derived from patented human embryonic stem ES cell technology. Chemicon is the first broad commercial collaborator...

  Tags: Chemicon International Inc., Serologicals Corp.

• Chemicon International, a Serologicals subsidiary, acquired the assets of Specialty Media, a division of Cell & Molecular Technology, for $6.5 million in cash

  - 2005-05-15

  Chemicon International, a Serologicals subsidiary, acquired the assets of Specialty Media, a division of Cell & Molecular Technology, for $6.5 million in cash. Specialty Media develops and supplies stem cell culture media formulations and supplements, cells and research reagent tools for life sciences. Chemicon expects the acquisition to generate $4...

  Tags: Chemicon International Inc.